Trastuzumab Deruxtecan (Enhertu)

Canada’s Drug Agency (CDA-AMC) recommends that Enhertu be reimbursed by public drug plans for the second-line treatment of adult patients with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti–HER2-based regimen for a time-limited period while additional evidence is generated if certain conditions are met. Please note that time-limited reimbursement refers to temporary reimbursement by the drug programs while additional evidence is generated and submitted for reassessment (i.e., this does not refer to the length of treatment or number of cycles administered). Enhertu should only be covered to treat adult patients with unresectable, locally advanced, or metastatic HER2-positive gastric or GEJ adenocarcinoma, have previously received trastuzumab-based treatment for locally advanced or metastatic disease, are in relatively good health, and do not have symptomatic spinal cord compression, clinically active central nervous system metastases, or current interstitial lung disease or pneumonitis. Enhertu should only be reimbursed if it is prescribed by clinicians with experience and expertise in treating gastric or GEJ adenocarcinoma and the cost of Enhertu is reduced.